Filing Flows › Bioventus (BVS) › Q4 2025
Bioventus (BVS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 5, 2026
Bioventus (BVS) reported revenue of $158M for the fourth quarter 2025 (Q4 2025), +3% from a year earlier and +14% from the quarter before. Operating margin was 12.3%, net earnings $14.8M (9.3% of revenue).
Bioventus, Q4 2025: revenue $158M (+3% year over year), operating margin 12.3%, net earnings $14.8M, operating cash flow $38.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $158M | +14% | +3% |
| Gross profit | $109M | +15% | +6% |
| Operating profit | $19.5M | +73% | +153% |
| Net earnings | $14.8M | +368% | — |
| Operating cash flow | $38.0M | +26% | +97% |
| Free cash flow | $37.4M | +26% | +99% |
What changed
Revenue was $157.9M in Q4 2025, up 3% year over year and up 14% from the previous quarter.
Gross margin was 68.9%, up 2.1 points from a year earlier. Operating profit was $19.5M, a 12.3% margin (up 7.3 points year over year). Of the extra revenue versus a year earlier, 277% reached operating profit, above the 5% margin then. Operating expenses fell 6% while revenue rose 3%. Net earnings were $14.8M. The effective tax rate was -22.4%.
Operating cash flow was $38.0M (up 97% year over year), 219% of net income including minority interests. Non-cash charges added back $11.7M of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items added $5.5M. Capital expenditures of $580K left free cash flow of $37.4M.
Questions
What was Bioventus' revenue in the fourth quarter 2025?
Bioventus (BVS) reported revenue of $158M for the fourth quarter 2025 (Q4 2025), +3% from a year earlier and +14% from the quarter before.
Was Bioventus profitable in the fourth quarter 2025?
Operating profit was $19.5M (12.3% of revenue) and net earnings $14.8M.
Source: Bioventus 10-K on SEC EDGAR.